Evidence map›Paper›PMID 40429825›Full record

ArticleInternational journal of molecular sciences2025

Efficient Design of Affilin

Anna M Diaz-Rovira, Jonathan Lotze, Gregor Hoffmann, Chiara Pallara, Alexis Molina, Ina Coburger, Manja Gloser-Bräunig, Maren Meysing, Madlen Zwarg, Lucía Díaz and 3 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anna M Diaz-RoviraLife Sciences Department, Barcelona Supercomputing Center, 08034 Barcelona, Spain.ORCID 0000-0001-7720-1351
Jonathan LotzeNavigo Proteins GmbH, 06120 Halle, Germany.
Gregor HoffmannNavigo Proteins GmbH, 06120 Halle, Germany.
Chiara PallaraNostrum Biodiscovery S.L., 08029 Barcelona, Spain.
Alexis MolinaNostrum Biodiscovery S.L., 08029 Barcelona, Spain.
Ina CoburgerNavigo Proteins GmbH, 06120 Halle, Germany.
Manja Gloser-BräunigNavigo Proteins GmbH, 06120 Halle, Germany.ORCID 0000-0001-7778-0664
Maren MeysingNavigo Proteins GmbH, 06120 Halle, Germany.
Madlen ZwargNavigo Proteins GmbH, 06120 Halle, Germany.
Lucía DíazNostrum Biodiscovery S.L., 08029 Barcelona, Spain.ORCID 0000-0001-8850-2571
Victor GuallarLife Sciences Department, Barcelona Supercomputing Center, 08034 Barcelona, Spain.ORCID 0000-0002-4580-1114
Eva Bosse-DoeneckeNavigo Proteins GmbH, 06120 Halle, Germany.
Sergi RodaNostrum Biodiscovery S.L., 08029 Barcelona, Spain.ORCID 0000-0002-0174-7435

Funding

Spanish Ministry of Science and Innovation FPU/03921
6 · The paper itself

Abstract

Engineered scaffold-based proteins that bind to concrete targets with high affinity offer significant advantages over traditional antibodies in theranostic applications. Their development often relies on display methods, where large libraries of variants are physically contacted with the desired target protein and pools of binding variants can be selected. Herein, we use a novel combined artificial intelligence/physics-based computational framework and phage display approach to obtain ubiquitin based Affilin

Indexed as

Protein EngineeringReceptor, ErbB-3Cell Surface Display TechniquesHumansLigandsPeptide LibraryProtein BindingERBB3 protein, humanLigandsPeptide LibraryReceptor, ErbB-3Affilin®HER3molecular modelingphage displayprotein designprotein–protein interactions

Identifiers

PMID40429825
PMCPMC12112719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.